CAR-T therapy involves some genetic engineering that is amazing; the culmination of work that began decades ago. But CAR T-cell therapy is not the classic form of gene therapy. Some refer to it as gene transfer that infuses copies of a normal gene or a modified gene into a genome in a more or less random fashion.
Population health should be about collective societal benefits like disease prevention and better health—better behavioral health included. Substantial investment is admittedly hard to make with no line of sight on where and when the cost benefits will come. It will take a leap of faith. Are you ready to jump?
A post on the Health Health Affairs blog last month offered insight into just what ACOs can bring to this process. The authors argued that while the applicability of ACOs to many areas of care delivery have been much examined, “discussions of the impact of ACOs on EOL care are conspicuously absent.”
Eliminating the cost-sharing payments (CSRs) to insurers to hold down out-of-pocket costs for low-income people who purchase individual health plans may wind up actually increasing overall federal spending by driving up premium subsidies to cover higher price plans.
Blame for the epidemic has focused on drugmakers, drug wholesalers, and physicians who prescribed opioids too liberally. This fall, fingers pointed at health insurers. Investigative reporting showed that coverage policies that restricted access to less addictive medications might have helped fueled the epidemic.
Broadening the Hospital Readmissions Reduction Program so that it is hospital-wide and not just focused on the five conditions currently included in the program would mean that safety-net hospitals would be hit with higher penalties. However, there may be ways to level the playing field if the switch ever takes place.
Transforming health care is harder than it looks. That’s partly because of a proliferation of pilot programs and point solutions that touch different parts of the elephant but fall short of actually unifying the vision. The time has come to make our way from volume to value.
This professor of pharmaceutical economics in the University of Minnesota College of Pharmacy says that the rising level of health care spending is unsustainable. He argues that drug price increases should be reviewed and PBMs should be regulated. “We need [a] bona fide rate regulation review body that can meaningfully evaluate the information presented by drug companies.”
That’s thanks to about 57 million unplanned sick days for workers. The prevalence of diabetes in the adult population grew from 10.6% in 2008 to 11.6% in 2016. It was at 11.5% for the first nine months of 2017.